4.7 Article

Development of a child-friendly oral drug formulation using liposomal multilamellar vesicle technology

期刊

出版社

ELSEVIER
DOI: 10.1016/j.ijpharm.2022.122107

关键词

Liposomes; Multilamellar Vesicle (MLV); Oral administration; Paediatric formulation

资金

  1. Canadian Institutes of Health Research (CIHR) [PJT-168861]
  2. Natural Science and Engineering Research Council in Canada (NSERC) [RGPIN-2017- 03787]
  3. Canada Foundation for Innovation (CFI) [35816]
  4. Mitacs Accelerate grant [IT13402]
  5. Mitacs and Precision Nanosystems Inc., Canada [IT13402, 183923]
  6. Angiotech Professorship in Drug Delivery
  7. King Abdulaziz City for Science and Technology (KACST) in Saudi Arabia
  8. German Research Foundation (DFG) [18004]
  9. Swiss National Science Foundation Postdoc Mobility Fellowship [423802991]

向作者/读者索取更多资源

This study reports a new method based on a liposomal multilamellar vesicle platform to prepare child-friendly oral formulations. The technique successfully converted weak-base drugs into liquid preparations and prevented drug taste interference by encapsulating the drugs completely. The formulation could be stored at room temperature and released the drug effectively in vitro and in vivo.
Many medicines are only available in solid dosage forms suitable for adults, and extemporaneous compounding is required to prepare formulations for children. However, this common practice often results in inaccurate dosing and unpleasant taste, reducing the medication adherence. Here, we report the development of a new method to prepare and compound child-friendly oral formulations based on a liposomal multilamellar vesicle (MLV) platform. MLVs composed of a phospholipid (DSPC) and cholesterol (55/45, molar ratio) were prepared using the standard thin film hydration method with 300 mM citric acid (pH 2), followed by an addition of aqueous sodium carbonate to adjust the exterior pH to 8-10 for creating a transmembrane pH gradient. Weakbase drugs, such as chloroquine (CQ) and hydroxychloroquine (HCQ), could be actively and completely loaded into the MLVs at a drug-to-lipid ratio of 15-20 wt%. This technique formulated weak-base drugs from the powder or tablet form into a liquid preparation, and the complete drug encapsulation would prevent contact between the drug molecules and the taste buds. The gradient MLV formulation could be preserved by lyophilization and stored at room temperature for at least 8 weeks. Upon reconstitution with water, the MLV formulation could completely encapsulate CQ at 20 wt%, which was comparable to the freshly prepared MLVs. The CQ-loaded MLV formulation could be stored at 4 degrees C for 2 weeks without drug leakage. In vitro release studies indicated that MLV could retain CQ in the simulated saliva, but released up to 50% and 30% of the drug in the simulated gastric and intestinal fluids, respectively. The orally delivered MLV-CQ formulation displayed higher CQ absorption in mice, with a 2-fold increase in the area under the curve (AUC) of the plasma profile compared to CQ solution. Our data suggest that the new MLV method could serve as a platform to prepare child-friendly oral formulation for weakbase drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据